Contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis

<h4>Background</h4> The aim of the study is to reveal the contribution of complete response (CR) to treatment to overall survival (OS) in patients with unresectable metastatic colorectal cancer. In addition, to evaluate progression-free survival (PFS) in patients who attained CR to treat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gulcan Bulut, Merve Guner Oytun, Elvina Almuradova, Mustafa Harman, Ruchan Uslu, Bulent Karabulut
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/be133167b4e84d62ad4d93c155ed2563
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:be133167b4e84d62ad4d93c155ed2563
record_format	dspace
spelling	oai:doaj.org-article:be133167b4e84d62ad4d93c155ed25632021-11-18T06:22:35ZContribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis1932-6203https://doaj.org/article/be133167b4e84d62ad4d93c155ed25632021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575296/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4> The aim of the study is to reveal the contribution of complete response (CR) to treatment to overall survival (OS) in patients with unresectable metastatic colorectal cancer. In addition, to evaluate progression-free survival (PFS) in patients who attained CR to treatment and to examine the clinicopathologic features of the patient group with CR. <h4>Methods</h4> This article is a retrospective chart review. Patients diagnosed with metastatic colorectal cancer were divided into two groups. The systemic treatment was compared with the patients who received a full response according to the Response Evaluation Criteria in Solid Tumors (RECIST1.1) and those who did not attain CR (progression partial response and stable response) in terms of both PFS and OS data, and the effect of attaining CR to treatment on prognosis was evaluated. <h4>Results</h4> A total of 222 patients were included in the study. 202 of 222 patients could be evaluated in terms of complete response. All data from their files were tabulated and analyzed retrospectively. The mean age of diagnosis of the study group was 60.13 ± 12.52 years. The total number of patients who attained CR to treatment was 31 (15.3%); 171 (84.6%) patients did not attain CR. Patients who had a CR had longer median PFS times than patients who did not have a CR (15.2 vs. 7.4 months, P<0.001). Patients who had CR had longer median survival times than patients who did not have a CR (39.2 vs. 16.9 months, P<0.001). In subgroup patients who underwent primary surgery, the number of patients who attained CR was statistically higher compared with the number of patients who did not attain CR (p<0.001). Complete response was less common in the presence of liver metastasis and bone metastasis (p = 0.041 and p = 0.046, respectively), had a negative prognostic effect. In other words, 89.1% of patients with liver metastasis, 100.0% of patients with bone metastasis, and 88.7% of those who died did not have a CR to the treatment. According to multivariate analysis, CR to treatment, primary surgery, first-line chemotherapy (combination compared with fluoropyrimidine), and no bone metastasis were found to be predictors for OS. <h4>Conclusion</h4> Providing CR with systemic treatment in patients with unresectable metastatic colorectal cancer (mCRC) contributes to prognosis. The primary resection in our secondary acquisitions from the study, the number of metastatic regions and the combination therapy regimens also contributed to the prognosis.Gulcan BulutMerve Guner OytunElvina AlmuradovaMustafa HarmanRuchan UsluBulent KarabulutPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Gulcan Bulut Merve Guner Oytun Elvina Almuradova Mustafa Harman Ruchan Uslu Bulent Karabulut Contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis
description	<h4>Background</h4> The aim of the study is to reveal the contribution of complete response (CR) to treatment to overall survival (OS) in patients with unresectable metastatic colorectal cancer. In addition, to evaluate progression-free survival (PFS) in patients who attained CR to treatment and to examine the clinicopathologic features of the patient group with CR. <h4>Methods</h4> This article is a retrospective chart review. Patients diagnosed with metastatic colorectal cancer were divided into two groups. The systemic treatment was compared with the patients who received a full response according to the Response Evaluation Criteria in Solid Tumors (RECIST1.1) and those who did not attain CR (progression partial response and stable response) in terms of both PFS and OS data, and the effect of attaining CR to treatment on prognosis was evaluated. <h4>Results</h4> A total of 222 patients were included in the study. 202 of 222 patients could be evaluated in terms of complete response. All data from their files were tabulated and analyzed retrospectively. The mean age of diagnosis of the study group was 60.13 ± 12.52 years. The total number of patients who attained CR to treatment was 31 (15.3%); 171 (84.6%) patients did not attain CR. Patients who had a CR had longer median PFS times than patients who did not have a CR (15.2 vs. 7.4 months, P<0.001). Patients who had CR had longer median survival times than patients who did not have a CR (39.2 vs. 16.9 months, P<0.001). In subgroup patients who underwent primary surgery, the number of patients who attained CR was statistically higher compared with the number of patients who did not attain CR (p<0.001). Complete response was less common in the presence of liver metastasis and bone metastasis (p = 0.041 and p = 0.046, respectively), had a negative prognostic effect. In other words, 89.1% of patients with liver metastasis, 100.0% of patients with bone metastasis, and 88.7% of those who died did not have a CR to the treatment. According to multivariate analysis, CR to treatment, primary surgery, first-line chemotherapy (combination compared with fluoropyrimidine), and no bone metastasis were found to be predictors for OS. <h4>Conclusion</h4> Providing CR with systemic treatment in patients with unresectable metastatic colorectal cancer (mCRC) contributes to prognosis. The primary resection in our secondary acquisitions from the study, the number of metastatic regions and the combination therapy regimens also contributed to the prognosis.
format	article
author	Gulcan Bulut Merve Guner Oytun Elvina Almuradova Mustafa Harman Ruchan Uslu Bulent Karabulut
author_facet	Gulcan Bulut Merve Guner Oytun Elvina Almuradova Mustafa Harman Ruchan Uslu Bulent Karabulut
author_sort	Gulcan Bulut
title	Contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis
title_short	Contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis
title_full	Contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis
title_fullStr	Contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis
title_full_unstemmed	Contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis
title_sort	contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: a retrospective analysis
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/be133167b4e84d62ad4d93c155ed2563
work_keys_str_mv	AT gulcanbulut contributionofcompleteresponsetotreatmenttosurvivalinpatientswithunresectablemetastaticcolorectalcanceraretrospectiveanalysis AT merveguneroytun contributionofcompleteresponsetotreatmenttosurvivalinpatientswithunresectablemetastaticcolorectalcanceraretrospectiveanalysis AT elvinaalmuradova contributionofcompleteresponsetotreatmenttosurvivalinpatientswithunresectablemetastaticcolorectalcanceraretrospectiveanalysis AT mustafaharman contributionofcompleteresponsetotreatmenttosurvivalinpatientswithunresectablemetastaticcolorectalcanceraretrospectiveanalysis AT ruchanuslu contributionofcompleteresponsetotreatmenttosurvivalinpatientswithunresectablemetastaticcolorectalcanceraretrospectiveanalysis AT bulentkarabulut contributionofcompleteresponsetotreatmenttosurvivalinpatientswithunresectablemetastaticcolorectalcanceraretrospectiveanalysis
_version_	1718424504006344704

Contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis

Ejemplares similares